Hans Klingemann

Dr. Hans Klingemann serves as Chief Science Officer for Cellular products at ImmunityBio. Before the merger, he was Vice President of Research & Development at Nantkwest, a position he held since 2012. Prior to joining NantKwest, Dr. Klingemann was the Director of Stem Cell Transplant and Malignant Hematology at Tufts University Medical Center in Boston. Previously, he led the Bone Marrow Transplant & Cell Therapy Section at Rush University Medical Center, where he established the first clinical GMP Cell Therapy facility in the Chicago area. Dr. Klingemann has conducted NCI-supported research on how to engineer the patient’s immune system to fight cancer, resulting in over 200 peer-reviewed publications. While at Vancouver Bone Marrow Transplant program, he directed a NCI-C funded immunotherapy lab that developed the NK-92 cell line. Over the past several years, he has worked with a team of scientists at Nantkwest/ImmunityBio to further engineer NK-92 (aNK) cells to become IL-2 independent, express a high affinity Fc receptor, as well as various chimeric antigen receptors. Dr. Klingemann received his medical and science training in Germany, and completed a fellowship at the Fred Hutchinson Cancer Research Center in Seattle, Washington.